© Reuters. FILE PHOTO: A woman receives the Johnson and Johnson COVID-19 vaccination in Houghton, Johannesburg, South Africa, August 20, 2021. REUTERS/ Sumaya Hisham
(Reuters) – U.S. Food and Drug Administration scientists said on Wednesday they did not have time to analyze data submitted by Johnson & Johnson (NYSE:) on a booster dose of its single-dose COVID-19 vaccine, in a rare case where the agency relied on a company’s analyses to brief its advisory panel.
An outside panel of experts will meet on Friday to discuss whether a booster dose of J&J’s vaccine is safe and effective anywhere between two months and six months after taking the original dose.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
For all the latest Business News Click Here